Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 20/20 | 1.00 |
| ▸ | HTR7 | P34969 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6189689 | 0.99 | HTR6 (0.98) | HTR6HTR7HTR1AHTR2CHTR2B | |
| Sb-399885 SCHEMBL29386696 | 0.91 | HTR6 (1.00) | HTR6HTR7HTR1AHTR2CHTR2B | |
| Sb-399885 SCHEMBL5459605 | 0.91 | HTR6 (1.00) | HTR6HTR7HTR1AHTR2CHTR2B | |
| Sb-399885 SCHEMBL3202031 | 0.90 | HTR6 (0.98) | HTR6HTR7HTR1AHTR2CHTR2B | |
| SCHEMBL6185701 | 0.90 | HTR6 (1.00) | HTR6HTR7HTR1AHTR2CHTR2B | |
| SCHEMBL6186080 | 0.90 | HTR6 (1.00) | HTR6HTR7HTR1AHTR2CHTR2B | |
| SCHEMBL6187994 | 0.90 | HTR6 (1.00) | HTR6HTR7HTR1AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL6187906 | 0.89 | HTR6 (0.98) | HTR6HTR7HTR1AHTR2CHTR2B | |
| SCHEMBL6187565 | 0.89 | HTR6 (0.88) | HTR6HTR7HTR1AHTR2CHTR2B | |
| SCHEMBL6186629 | 0.89 | HTR6 (1.00) | HTR6HTR7HTR1AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0994862-B1 | SULPHONAMIDE DERIVATIVES BEING 5-HT6 RECEPTOR ANTAGONISTS AND PROCESS FOR THEIR PREPARATION | SMITHKLINE BEECHAM PLC (GB) | 2005-06-01 | — | — | EP | claimed |
| CN-1087294-C | Novel compounds | SMITHKLINE BEECHAM PLC (GB) | 2002-07-10 | — | — | CN | claimed |
| US-6316450-B1 | PIPERAZINE COMPOUNDS FOR TREATING DEPRESSION AND ANXIETY | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-11-13 | — | — | US | claimed |
| EP-0994862-A2 | SULPHONAMIDE DERIVATIVES BEING 5-HT6 RECEPTOR ANTAGONISTS AND PROCESS FOR THEIR PREPARATION | SMITHKLINE BEECHAM PLC (GB) | 2000-04-26 | — | — | EP | claimed |
| WO-1999002502-A2 | SULPHONAMIDE DERIVATIVES BEING 5-HT6 RECEPTOR ANTAGONISTS AND PROCESS FOR THEIR PREPARATION | SMITHKLINE BEECHAM PLC (GB) | 1999-01-21 | — | — | WO | claimed |
| EP-0994862-B1 | SULPHONAMIDE DERIVATIVES BEING 5-HT6 RECEPTOR ANTAGONISTS AND PROCESS FOR THEIR PREPARATION | SMITHKLINE BEECHAM PLC (GB) | 2005-06-01 | — | — | EP | disclosed |
| US-20040034036-A1 | N-(3,5-dichloro-2-methoxyphenyl)-4-methoxy-3-piperazin-1-yl-benzenesulfonamide | SMITHKLINE BEECHMAN P.L.C. (GB) | 2004-02-19 | — | — | US | disclosed |
| CN-1087294-C | Novel compounds | SMITHKLINE BEECHAM PLC (GB) | 2002-07-10 | — | — | CN | disclosed |
| US-6316450-B1 | PIPERAZINE COMPOUNDS FOR TREATING DEPRESSION AND ANXIETY | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-11-13 | — | — | US | disclosed |
| EP-0994862-A2 | SULPHONAMIDE DERIVATIVES BEING 5-HT6 RECEPTOR ANTAGONISTS AND PROCESS FOR THEIR PREPARATION | SMITHKLINE BEECHAM PLC (GB) | 2000-04-26 | — | — | EP | disclosed |
| WO-1999002502-A2 | SULPHONAMIDE DERIVATIVES BEING 5-HT6 RECEPTOR ANTAGONISTS AND PROCESS FOR THEIR PREPARATION | SMITHKLINE BEECHAM PLC (GB) | 1999-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034036-A1 | N-(3,5-dichloro-2-methoxyphenyl)-4-methoxy-3-piperazin-1-yl-benzenesulfonamide | PMP22, CNR2, SNCA | HTR6 60/4885HTR7 185/4885HTR1A 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.